I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0, missing the estimate of USD 50 K.
EBIT: As of FY2026 Q2, the actual value is USD -6.6 M.
Cash Position
CervoMed Inc. reported cash, cash equivalents, and marketable securities of approximately $24.9 million as of June 30, 2026, an increase from $20.9 million as of December 31, 2025. The company completed two equity financings in June 2026, generating aggregate gross proceeds of approximately $20.5 million, before deducting approximately $1.9 million in offering fees and expenses. These financings are expected to extend the company’s cash runway through the third quarter of 2027.
Grant Revenue
For the three months ended June 30, 2026, CervoMed Inc. recognized no grant revenue, compared to approximately $1.8 million for the same period in 2025. This decrease is attributed to the completion of the Phase 2b RewinD-LB trial in mid-2025, with no further funding available or expected from the previously awarded $21.3 million grant by the National Institute on Aging.
Research and Development (R&D) Expenses
R&D expenses for the three months ended June 30, 2026, were approximately $4.3 million, a decrease from approximately $5.1 million for the same period in 2025. The reduction was primarily due to decreased costs related to the completed RewinD-LB trial and other clinical and nonclinical activities, partially offset by increased costs for chemistry, manufacturing, and controls-related activities for neflamapimod, ongoing Phase 2a clinical trials in nfvPPA and RAS, and higher personnel and outsourced consulting costs.
General and Administrative (G&A) Expenses
G&A expenses for the three months ended June 30, 2026, were approximately $2.4 million, down from approximately $3.3 million for the same period in 2025. This decrease was mainly due to lower headcount, the absence of severance costs present in the prior year, and reductions in professional fees and stock-based compensation expense.
Net Loss
CervoMed Inc. reported a net loss of approximately -$6.6 million for the three months ended June 30, 2026, compared to a net loss of approximately -$6.3 million for the same period in 2025. The -$0.3 million increase in net loss was primarily due to a -$1.8 million decrease in grant revenue, partially offset by a -$1.7 million decrease in total operating expenses.
Operational Metrics and Program Highlights
CervoMed Inc. is prioritizing a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB). Neflamapimod received an Innovation Passport designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for DLB development in August 2026 and a patent allowance in June 2026 covering its use in DLB until 2042. Enrollment for the Phase 2a clinical trial evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) was completed in July 2026 with 25 participants, and enrollment in the Phase 2a RESTORE trial for recovery after stroke (RAS) ended in June 2026.
Outlook / Guidance
CervoMed Inc. expects to continue pursuing a strategic partnership for the Phase 3 clinical trial of neflamapimod in DLB. For nfvPPA, biomarker data will be presented in October and November 2026, with initial topline clinical data expected in the first quarter of 2027. The company anticipates dosing the first patient in the EXPERTS-ALS trial for amyotrophic lateral sclerosis (ALS) by the end of 2026 and reporting topline data from the Phase 2a RESTORE trial for RAS in the second half of 2026.